Focus: Bavarian Nordic is a Denmark-headquartered biotech company specializing in vaccines for infectious diseases and oncology, operating at mid-cap scale with 1,001–5,000 employees. The company focuses on viral vaccine platform technologies with an expansive pipeline spanning endemic diseases, emerging pathogens, and therapeutic cancer vaccines.
Profile data last refreshed 6h ago · AI intelligence enriched 1mo ago
Growing — net +8 jobs in 30d
25 jobs added vs 17 removed. Steady team buildout.
Attractive for vaccine and immunology specialists seeking commercial-stage upside and Phase 3 catalysts, but governance tensions and opaque financials warrant due diligence before committing.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Bavarian Nordic
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Bavarian Nordic's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Bavarian Nordic Seeks Brazil Approval for Chikungunya Vaccine - t.co
Bavarian Nordic Seeks Brazil Approval for Chikungunya Vaccine t.co
Bavarian Nordic partner applies for approval of chikungunya vaccine in Brazil - medwatch.com
Bavarian Nordic partner applies for approval of chikungunya vaccine in Brazil medwatch.com
Bavarian Nordic completes share buyback - medwatch.com
Bavarian Nordic completes share buyback medwatch.com
Bavarian Nordic splits up commercial division – appoints global head of emergency vaccines - medwatch.com
Bavarian Nordic splits up commercial division – appoints global head of emergency vaccines medwatch.com
Bavarian Nordic wins Canadian approval for chikungunya vaccine - medwatch.com
Bavarian Nordic wins Canadian approval for chikungunya vaccine medwatch.com
Bavarian Nordic receives smallpox vaccine order worth more than USD 100m - medwatch.com
Bavarian Nordic receives smallpox vaccine order worth more than USD 100m medwatch.com
Showing 6 of 10 news items
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Expert Recommendations to Strengthen Chikungunya Outbreak Surveillance and Reporting for Traveler Health Protection.
Protocol for a phase 3, randomized, double-blind clinical trial evaluating the safety and immunogenicity of the MVA-BN® vaccine against mpox in children aged 4 to less than 24 months in the Democratic Republic of the Congo: Data to guide future paediatric vaccination strategies.
Showing 5 of 10 publications